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Precision medicine (PM) is an emerging data-driven health care approach that integrates
phenotypic, genomic, epigenetic, and environmental factors unique to an individual.
The goal of PM is to facilitate diagnosis, predict effective therapy, and avoid adverse
reactions specific for each patient. The forefront of PM is in oncology; nonetheless,
it is developing in other fields of medicine, including rheumatology. Recent studies
on elucidating the genetic architecture of polygenic and monogenic rheumatological
diseases have made PM possible by enabling physicians to customize medical treatment
through the incorporation of clinical features and genetic data. For complex inflammatory
disorders, the prevailing paradigm is that disease susceptibility is due to additive effects
of common reduced-penetrance gene variants and environmental factors. Efforts have
been made to calculate cumulative genetic risk score (GRS) and to relate specific
susceptibility alleles for use of target therapies. The discovery of rare patients with
single-gene high-penetrance mutations informed our understanding of pathways driving
systemic inflammation. Here, we review the advances in practicing PM in patients with
primary systemic vasculitides (PSVs). We summarize recent genetic studies and discuss
current knowledge on the contribution of epigenetic factors and extracellular vesicles
(EVs) in disease progression and treatment response. Implementation of PM in PSVs is
a developing field that will require analysis of a large cohort of patients to validate data
from genomics, transcriptomics, metabolomics, proteomics, and epigenomics studies
for accurate disease profiling. This multi-omics approach to study disease pathogeneses
should ultimately provide a powerful tool for stratification of patients to receive tailored
optimal therapies and for monitoring their disease activity.
Keywords: precision medicine, vasculitis, vasculitides, genome-wide association studies, epigenetics,
extracellular vesicles, monogenic systemic autoinflammatory diseases

INTRODUCTION
Precision medicine (PM) can be defined as tailored medical care that is primarily based upon
understanding the molecular sequence of biologic events causal to disease and critical for
diagnosis and therapy. The term precision medicine should be distinguished from the term
personalized medicine whereby prevention and treatment are being developed uniquely for each
patient, although these two terms are used interchangeably (1). Both communicate a concept of
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individualized medicine, although in PM, the focus is on
identifying health care approaches that will be effective for a
group of patients who share similar genetic, environmental, and
lifestyle disease susceptibility factors. Recognizing subgroups of
patients with similar disease risk factors will ensure that they will
receive optimal treatment to improve their quality of life and
health outcomes.
Primary systemic vasculitides (PSVs) (Table 1) are a
heterogeneous group of diseases in their etiology, clinical
presentation, and response to therapy. Severity and location
of symptoms vary greatly, and most classification schemes
that attempt to advance clinicians the ability to diagnose and
treat patients, are based on blood vessel size, autoantibodies
profile [e.g., anti-neutrophil cytoplasmic antibody (ANCA)], and
histopathological findings. In addition to genetic predisposition,
there is a role for environmental factors, including exposure
to drugs and infectious agents, in the pathogenesis, and
prognosis of PSVs. The past decade has witnessed major
advances in genetics research that have improved our
understanding on molecular mechanisms in PSVs. New
sequencing technologies and high-throughput genotyping
arrays used for genome-wide association studies (GWAS)
generated vast amount of data that will require validation
by meta-analysis in large cohorts of patients. Discovery of
monogenic diseases mimicking PSVs offered additional insights
on biochemical pathways that are shared between rare and more
common forms of vasculitis. Recent advances in epigenetic
research support the role of extracellular vesicles (EVs) in the
pathogenesis of PSVs, which could be used for developing
novel biomarkers to monitor disease activity, prognosis, and
treatment outcomes.
Herein, we discuss the up-to-date knowledge on the genetic
predisposition to PSVs and review recent clinical research studies
aimed to further our understanding of the pathogeneses and
outcomes of vasculitides.

TABLE 1 | Chapel Hill Consensus Conference Nomenclature (CHCC 2012) of
vasculitides (2).

GWAS IN PSVs

the locus have been shown to play a major role in susceptibility
to disease (4). In primary vasculitides (PSVs), GWAS have been
performed primarily in Kawasaki disease (KD) and Behçet’s
disease (BD) (Table 2) (5–42, 44–46).

Large-vessel vasculitis (LVV)
• Takayasu arteritis (TAK)
• Giant cell arteritis (GCA)
Medium-vessel vasculitis (MVV)
• Polyarteritis nodosa (PAN)
• Kawasaki disease (KD)
Small-vessel vasculitis (SVV)
• Antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV)
◦ Microscopic polyangiitis (MPA)
◦ Granulomatosis with polyangiitis (Wegener’s) (GPA)
◦ Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA)
• Immune complex SVV
◦ Anti–glomerular basement membrane (anti-GBM) disease
◦ Cryoglobulinemic vasculitis (CV)
◦ IgA vasculitis (Henoch-Schönlein purpura) (IgAV/HSP)
◦ Hypocomplementemic urticarial vasculitis (HUV) (anti-C1q vasculitis)
Variable vessel vasculitis (VVV)
• Behçet’s disease (BD)
• Cogan’s syndrome (CS)
Single-organ vasculitis (SOV)
• Cutaneous leukocytoclastic angiitis
• Cutaneous arteritis
• Primary central nervous system vasculitis
• Isolated aortitis
• Others
Vasculitis associated with systemic disease
• Lupus vasculitis
• Rheumatoid vasculitis
• Sarcoid vasculitis
• Others
Vasculitis associated with probable etiology
• Hepatitis C virus–associated cryoglobulinemic vasculitis
• Hepatitis B virus–associated vasculitis
• Syphilis-associated aortitis
• Drug-associated immune complex vasculitis
• Drug-associated ANCA-associated vasculitis
• Cancer-associated vasculitis
• Others (e.g., varicella zoster virus–associated vasculitis)

GWAS have been used, following the completion of the Human
Genome project in 2003 and the International HapMap Project
in 2005, to identify association of common and reducedpenetrance variants, termed single nucleotide polymorphisms
(SNPs), with human traits or diseases (3). The primary goal
of GWAS has been to elucidate the biology of polygenic and
complex human diseases, which can be translated toward the
development of novel therapeutics. GWAS have also been used
to study gene-environment interactions, response to therapies,
and more recently for risk prediction. GWAS are based on the
genotyping of large cohorts of patients and ancestry-matched
controls for SNPs in the entire genome. These associations are
tested with gene variants that have a minor allele frequency
(MAF) higher than 5% in the general population and are
considered significant at the p-value genome-wide threshold of
5 × 10−8 (4). For a number of autoimmune disorders, SNPs
in the human leukocyte antigen (HLA) [also known as major
histocompatibility complex (MHC)] and genes encoded within
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Kawasaki Disease
KD is an acute, self-limited vasculitis that typically affects infants
and children under the age of 5 years. Coronary artery aneurysms
(CAAs) occur in 25% of untreated patients and may lead to
ischemic heart disease, myocardial infarction, and sudden death
at a young age. The pathogenesis of KD remains unknown;
however, it is thought that host genetics play an important
role in susceptibility and disease outcome. Interestingly, the
incidence of KD is up to 50-fold higher in children of
Asian descent. Epidemiologic and clinical features of KD also
strongly support an infectious etiology in genetically predisposed
children (47).
GWAS in KD have identified a number of susceptibility
SNPs/genes that contribute to the risk of KD (HLA, FCGR2A,
SLC8A1, ZFHX3, NMNAT2, BLK, DAB1, HCP5, COPB2, ERAP1,
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TABLE 2 | Genome-wide association studies (GWAS) in primary systemic vasculitides (PSVs).
Related risk and references

Genes from GWAS

Therapeutic implications

HLA, HCP5, FCGR2A, BLK, SLC8A1, CD40, NMNAT2, DAB1, COPB2,
NAALADL2, IGHV, ZFHX3, NFKBIL1, ERAP1, EBF2, CACNB2, LTA, and
LEF1

SNP in SLC8A1 (calcium signaling pathway) can be
proof for using calcineurin inhibitors in KD

Kawasaki Disease (KD)
Susceptibility genes for KD (5–16)

Susceptibility genes for cardiovascular TIAM1, NEBL, PLCB4/PLCB1, TUBA3C, SLC8A1, PELI1, KCNN2, TIFAB,
and AGT
disease in KD (8, 12, 17–22)
Susceptibility genes for intravenous
BCL2L11 and SAMD9L
immunoglobulin (IVIG) resistance in KD
(23, 24)

BCL2L11 and SAMD9L: prediction of IVIG resistance

Behçet’s Syndrome (BS)
Susceptibility genes for BS (25–34)

HLA-B51, STAT4, IL10, GIMAP, IL23R-IL12RB2, CCR1, ERAP1, KLRC4, Inhibition of IL-12/IL-23 pathway activation may be a
treatment target
FUT2, IL12A, NAALADL2, YIPF7, CPVL, UBAC2, LOC100129342,
UBASH3B, and KIAA1529

Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV)
Related with anti-MPO AAV (35)

HLA-DQ

Related with anti-PR3 AAV (35, 36)

HLA-DP, SERPINA1, and PRTN3

Related with AAV (36, 37)

PTPN22, SEMA6A

Takayasu Arteritis (TAK)
Susceptibility genes for TA (38–41)

HLA-B/MICA, HLA-DQB1/HLA-DRB1, FCGR2A/FCGR3A, IL12B,
RPS9/LILRB3, IL6, PTK2B, LILRA3/LILRB2, DUSP22, KLHL33,
HSPA6/FCGR3A, the intergenic locus on chromosome
chromosome21q.22, MICB, and HLA-B*52 (poor prognosis)

Immunoglobulin A Vasculitis/Henoch-Schönlein Purpura (IgAV/HSP)
Susceptibility locus for IgAV/HSP (42)

HLA-DRB1

Giant cell arteritis (GCA)
Susceptibilty genes for GCA (43)

HLA-DRB1*04, PLG, and P4HA2

evidence for the role of Ca2+ -mediated signaling pathways in the
pathogenesis of KD and for the use of calcineurin inhibitors (49).
Lv et al. (46) used statistically significant candidate variants
from multiple GWAS and other gene association studies
for pathways analysis. This investigation showed that KD
susceptibility genes are enriched in functional networks for
calcium ion homeostasis and immune responses and highlighted
the role of nuclear transcription factor of activated T cells (NFAT) and nuclear factor (NF) kappa light chain enhancer of
activated B cells (NF-κB) in the pathogenesis of KD.
Another indication from GWAS for the use of new therapies
in KD has come from the study by Chang et al. (44). The
promoter variant, rs2736340, in the B lymphoid tyrosine kinase
(BLK) gene was significantly associated with susceptibility to KD
in multiple Asian populations [odds ratio (OR) = 1.498, 1.354–
1.657; p = 4.74 × 10(−31)]. The transformed and primary B cells
with the risk allele express significantly lower levels of BLK and
have reduced signaling downstream of B cell receptors. These
data suggest a role for humoral immunity in the pathogenesis of
the acute stage of KD (44). Although B cells and autoantibodies
have been found in blood samples of KD patients, their role,
whether they are causal or bystanders of an activated immune
system or specific to an infectious agent in the etiology of KD, is
currently unknown (50).
Standard treatment for KD consists of a single infusion of
high-dose IVIGs and high-dose aspirin (until the fever has

NAALADL2, CD40, NFKBIL1, IGHV, EBF2, CACNB2, LTA,
and LEF1) (5–16) to the risk of cardiovascular disease in
KD (TIAM1, NEBL, PLCB4/PLCB1, TUBA3C, SLC8A1, PELI1,
KCNN2, TIFAB, and AGT) (8, 12, 17–22) and to the risk
of intravenous immunoglobulin (IVIG) resistance (BCL2L11
and SAMD9L) (23, 24). Involvement of the HLA region in
susceptibility to KD has been controversial and has not been
replicated across different ancestral groups.
Shimizu et al. (12) identified three functional SNPs in
the solute carrier family 8, member 1 (SLC8A1) gene to be
associated with susceptibility to KD in Japanese and European
cohorts (meta analysis p = 0.0001). SLC8A1 encodes NCX1
(a sodium/calcium exchanger) that functions as a bidirectional
sodium/calcium channel. Patients homozygous for the risk allele
(rs13017968) have higher rates of coronary artery abnormalities.
Homozygosity for rs13017968 is associated with an increase in
Ca2+ flux in EBV-transformed B cells of healthy individuals.
The NCX1 protein expression was detected in the postmortem
coronary artery tissue of a young KD patient. Another study by
Onouchi et al. (48) found a coding SNP (rs3741596) in the ORAI
Calcium Release-Activated Calcium Modulator 1 (ORAI1) gene
to be significantly associated with KD in Japanese patients (meta
analysis p = 0.00041). Interestingly, frequency of the risk allele is
more than 20 times higher in Japanese compared to Europeans,
which may account for higher prevalence of KD in the Japanese
population. Together, these genetic and functional data provide
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recent immunogenetic findings from GWAS provide clues to its
pathogenesis (53, 54).
HLA-B∗ 51 remains the most significant genetic susceptibility
factor for BD in multiple populations; however, it accounts for
<20% of the genetic risk (55, 56). The ongoing controversy
is about whether the disease association with HLA-B∗ 51 is
attributed to a role of this variant itself or is due to its linkage
disequilibrium (LD) with another variant in the region. There
are also other BD disease-associated amino acids variants in
the HLA-B locus that are thought to reside within the antigenbinding grove of the molecule (57). The association between
specific MHC class I alleles and certain disease manifestations
have been reported (58–61). A meta-analysis based on 72 studies
in 74 study populations revealed moderate association of HLAB∗ 51/B5 with male gender and high prevalence of eye and
mucocutaneous involvement (60).
GWAS have identified a number of population-specific
associations in the following genes: IL23R-IL12RB2, IL10,
TNFAIP3, STAT4, CCR1-CCR3, KLRC4, ERAP1, and FUT2.
Variants in some genes, including KIAA1529, UBASH3B, GIMAP,
IL12A, NAALADL2, YIPF7, CPVL, LOC100129342, and UBAC2,
did not reach genome-wide significance (p < 5.0 × 10−8 )
(25–34). Most of these alleles act as susceptibility factors,
while some variants appear to be protective. BD-risk alleles
in the IL10 susceptibility gene locus were the first variants
identified outside of the HLA region by GWAS in Turkish
and Japanese populations (29, 30). The SNP rs1518111 was
subsequently replicated in Middle Eastern Arab, Greek, British,
Korean, Iranian, and Han-Chinese samples and is today the only
variant consistently associated with susceptibility to BD across all
ancestries (57).
More recent studies investigated whether there is
evidence for interaction (epistasis) among BD susceptibility
genes. The endoplasmic reticulum (ER)-associated protease
(ERAP1) haplotype tagged by the coding variant, rs17482078
(p.Arg725Gln), has a large effect with an OR of 3.78 in
patient carriers for HLA-B∗ 51. Interestingly, the same variant
rs17482078 is protective for psoriasis and ankylosing spondylitis
(AS). ERAP1 is an enzyme that clips proteasome-processed
peptides in the ER before these peptides are loaded on
class I HLA molecules (56). The epistasis observed between
HLA-B∗ 51 and the risk haplotype of ERAP1 suggests that
an HLA class I-peptide presentation contributes to BD.
The difference between risk and protection conferred
by the ERAP1 haplotype may be explained by altered
binding affinities among specific peptides, trimmed or not
trimmed by the ERAP1 variant, for different HLA class I
molecules (62).
Dense genotyping of immune-related loci extended the list of
susceptibility genes to include risk alleles in IL1A-IL1B, IRF8,
CEBPB-PTPN1, and ADO-EGR2 genes in the Turkish set of
1,900 cases and 1,779 controls. This study implicated the innate
immune response to microbial exposure in susceptibility to BD
(63). Bakir-Gungor et al. reported new BD-associated common
variants in pathways, including focal adhesion, complement
and coagulation cascades, mitogen-activated protein kinases
(MAPK) signaling, proteasome pathways, extracellular matrix

resolved); however, the mechanism of action remains elusive.
Because IVIG therapy is the mainstay of treatment for KD,
there has been interest to study the effect of SNPs and copy
number variants (CNVs) on the function of receptors for
IgG, the Fc-gamma receptors (FcγRs). There are five genes
encoding the low-affinity FcγRs (FCGR2A, FCGR2B, FCGR2C,
FCGR3A, and FCGR3B) that are clustered in the FCGR2/3 locus.
Recently, Nagelkerke et al. published a study that evaluated
the previously reported genetic association with the rs1801274
variant in this gene locus. The FCGR2A coding SNP rs1801274
has been validated in a number of KD ancestry cohorts and
was shown to cause a difference in the ability of FcγRIIa to
bind the human IgG2 immunoglobulin isotype. This new study
defined haplotype blocks (set of closely linked alleles/markers
that are inherited together) across the FCGR2/3 gene locus in
over 4,000 individuals from different populations. The FCGR2CORF haplotype has stronger susceptibility to KD in the European
cohort than the previously reported risk allele rs1801274.
However, the FCGR2C-ORF haplotype is extremely rare in
Asians and thus cannot explain the high prevalence of KD in
Asian populations. This research points out the importance of
proper interpretation of genetic association studies in the context
of patients’ ancestry (51).
Kuo et al. developed a genetic model to predict IVIG
resistance in KD. They identified 11 candidate SNPs in ADTRP,
KLF6, EX0C2, ZNF438-ZEB1, and MIR548A3-ZPLD1 genes to
calculate a weighted genetic risk score (wGRS) in 126 IVIG
responders and 24 IVIG non-responders (52). Patients with IVIG
resistance had higher wGRS scores than individuals who were
IVIG responsive; however, the wide confident intervals (CIs) for
the OR suggest that these findings should be replicated in larger
cohorts of patients.
Kim et al. (24) recently identified a new gene locus, SAMD9L,
that is associated with IVIG resistance in Korean and Japanese
KD cohorts. The meta-analysis of IVIG non-responders (n =
317) and IVIG responders (n = 1221) showed the association of
the common intronic variant (rs28662; MAF = 13% in gnomAD)
with IVIG resistance [(OR) = 4.30, p = 5.3 × 10−6 ]. This SNP
was predicted to change the motif for transcription factor binding
site and was also associated with differential expression of the
SAMD9L gene in lymphoblastoid cell lines. Previously, variants
in SAMD9L have been associated with susceptibility for systemic
lupus erythematosus, systemic sclerosis, and other immunerelated diseases, such as juvenile myelomonocytic leukemia,
acute myeloid leukemia, myelodysplastic syndrome, hepatitisB-related hepatocellular carcinoma, and ataxia-pancytopenia
syndrome. However, the role of SAMD9L in immune signaling
pathway is unclear (24).

Behçet’s Disease
BD is a chronic multisystem inflammatory disorder characterized
by recurrent oral/genital ulcers, ocular involvement, skin
lesions/pathergy, presenting with remissions and exacerbations.
The disease is common in populations living along the
ancient Silk Road: Turkish, Iranian, Chinese, Korean, and
Japanese. Classic BD is a complex disease with a strong genetic
predisposition. Although the etiology of BD remains unclear,
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levels of circulating PR3 and higher production of anti-PR3
autoantibodies. Population difference in HLA-class II genotype
frequency plays a role in the epidemiology of this disease.
Among AAVs, GPA and PR3-AAV are prevalent in European
populations, whereas MPA and MPO-AAV are predominant in
the Japanese population. In the North American population, the
HLA- DPB1∗ 04 has the strongest association with GPA, whereas
in the Japanese population, HLA- DRB1∗ 09:01 is strongly
associated with MPA (68–70).
Other notable variants outside the HLA region include
alleles in protein tyrosine phosphatase non-receptor type 2
(PTPN22) gene, which negatively regulates the production of an
immunosuppressive cytokine interleukin (IL-10) (71). The gainof-function risk allele, p.Arg260Trp, is linked to GPA-AAV in
addition to a number of other autoimmune diseases (72, 73). A
non-coding SNP in the vicinity of SEMA6A is linked to GPA in
the GWAS study of Caucasian cohort of 528 patients and at a
genome-wide signficance (p = 2.09 × 10−8 ). The SEMA6A gene
codes for semaphorin 6A and is highly expressed in dendritic
cells; however, its function is unclear (37).
Lower and higher copy number variants in the FCGR3B gene
and a higher DEFB4 gene copy number have been associated
with risk for AAV (74–76). A possible relationship between the
FCGR3B copy number and susceptibility to AAV needs to be
clarified experimentally (77).
Lee et al. performed gene-ontology (GO) enrichment and
protein–protein interaction (PPI) networks analysis of significant
risk alleles to identify the key pathophysiological pathways in the
pathogenesis of AAV. The most significant pathways include the
processing of antigens via HLA class II, T-cell receptor signaling,
and interferon (IFN)-γ mediated signaling pathways (78).

(ECM)–receptor interaction, and transforming growth factor-β
(TGFβ) signaling both in Japanese and Turkish populations (64).
Targeted sequencing of candidate immunological genes has
revealed the contribution of rare non-synonymous variants of
NOD2, TLR4, IL23, and MEFV in the BD pathogenesis. In
particular, heterozygosity for a common high-penetrance familial
Mediterranean fever (FMF)-associated mutation p.Met694Val is
significantly associated with BD risk in the Turkish population,
although not in Japanese patients due to its absence in the
Asian populations (65). MEFV encodes pyrin, which regulates
caspase-1-mediated interleukin (IL)-1β production.
Nakano et al. investigated the functional effect of GWASidentified BD risk alleles in IL-10 and CCR1. They observed
a differential protein expression of IL10 and CCR1 in M1 vs.
M2 macrophages (Mφ) derived from BD patients. BD skin
lesions showed predominance of M1 Mφ. This study suggests
that targeting pathways and genes that play a role in the Mφ
polarization should be explored in the treatment of BD (66).
Taken together, GWAS have implicated a number of genes of
the innate and adaptive immunity with increased susceptibility
to BD. Whether inhibition of these molecular pathways will be
effective in the treatment of BD remains to be seen.

ANCA-Associated Vasculitis (AAV)
AAV is a heterogeneous group of disorders characterized by
necrotizing inflammation of small vessels and by the presence of
ANCA. The two most common ANCAs are the autoantibodies
that target the proteins: myeloperoxidase (MPO) and proteinase
3 (PR3). AAV includes the clinical syndromes of microscopic
polyangiitis (MPA), granulomatosis with polyangiitis (GPA), and
eosinophilic granulomatosis with polyangiitis (EGPA). ANCA
directed against PR3 are preferentially associated with GPA, and
anti-MPO is associated mainly with MPA and EGPA. Although
the role of ANCA in the pathogenesis of AAV is appreciated,
the mechanism for ANCA-mediated development of AAV is
not clear. Genetic predisposition and exposure to environmental
factors, such as drugs and infectious agents, are possible triggers
of excessive activation of neutrophils and injury to small blood
vessels. The clinical signs vary and may affect several organs, such
as the kidney, intestine, lung, and skin.
Currently, three GWAS have been performed in AAV. These
studies identified risk alleles in HLA-DQ, HLA-DP, HLA-DR,
SERPINA1, PTPN22, PRTN3, and SEMA6A genes as contributing
to AAV (35–37). A meta-analysis of 140 reported genetic variants
associated with AAV distinguished the most significant 33 alleles
in 15 genes (67). Twenty of these 33 genetic variants were present
in the HLA region, suggesting an important role for the antigen
presentation in the disease pathogenesis. Two GWAS showed
that the SNP association signal in the HLA region was fully
accounted for by HLA-DPB1∗ 04 allele (35, 37).
Lyons et al. established that MPA and GPA are two distinct
diseases based on their genetic profile (35). Anti-MPO positive
AAV (MPA) is strongly associated with the HLA-DQ, whereas
anti-PR3 AAV (GPA) is associated with the HLA-DP region
and the genes encoding α(1)-antitrypsin (SERPINA1) and serine
proteinase 3 (PRTN3) (35, 68). SERPINA1 is a major inhibitor
of PR3, and lower levels of α (1)-antitrypsin can lead to higher
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Takayasu Arteritis (TAK)
TAK is a large-vessel vasculitis that predominantly affects young
women and can cause organ-threatening ischemia, such as
pulseless limbs, aortic regurgitation, pulmonary infarct, and
kidney failure by occluding the aorta and/or its branches. TAK
is seen all over the world, but Eastern Asia, especially Japan,
has the highest incidence. The etiology of TAK is elusive,
but genetic predisposition is likely. Corticosteroids, anti-tumor
necrosis factor (TNF)-α, anti-IL-6, and abatacept are used for
induction of remission and with aim to prevent relapse.
GWAS have shown that HLA-B/MICA, HLA-DQB1/HLADRB1, FCGR2A/FCGR3A, IL12B, RPS9/LILRB3, IL6, PTK2B,
LILRA3/LILRB2, DUSP22, KLHL33, and HSPA6/FCGR3A and
the intergenic locus on chromosomes 21q.22, MICB, and HLAB∗ 52 are susceptibility gene loci in TAK (38–41). Risk alleles
in HLA-B/MICA and HLA-DQB1/HLA-DRB1 were identified
in Turkish and European cohorts of patients. Other notable
associations are in PSMG1, IL12, and IL23 gene loci but not
at the level of genome-wide significance (39). HLA-B∗ 52 allele
is related to poor prognosis in TAK (79, 80). Risk alleles in
the RPS9/LILRB3 locus and IL6 may have immunoregulatory
effects (38). The disease risk variant in RPS9/LILRB3, rs11666543
(p = 2.34 × 10−8 ), correlates with reduced mRNA expression
of the inhibitory leukocyte immunoglobulin-like receptor gene
LILRB3. One study proposed that risk alleles in the IL6 gene
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polymyalgia rheumatica. GCA is a potentially devastating
disease, with up to 25% of patients developing aneurysmal
disease and stroke. First-line treatment of GCA is a high-dose
glucocorticoid (GC), and it should be maintained until symptoms
are resolved.
GC resistance and adverse effects are main concerns for
treatment of patients with GCA (95). Other agents, such as
methotrexate and TNF inhibitors, have been used with limited
or no evidence of benefit. Recent studies implicated important
roles for TH 1- and TH 17-driven inflammatory cascades. Results
from new therapies with abatacept and ustekinumab have also
been promising.
In 2017, the first GWAS in GCA identified the HLA-DRB1∗04
as the strongest risk allele (43). This finding implies that GCA
is a predominantly HLA class II disease and is distinct from
the other large-vessel vasculitis, TAK, which is considered an
HLA class I disease. Carmona et al. (43) reported susceptibility
alleles in plasminogen (PLG) and prolyl 4-hydroxylase subunit
alpha 2 (P4HA2) genes in 10 different populations of European
ancestry at a genome-wide level of significance (rs4252134, p =
1.23 × 10−10 , OR = 1.28; and rs128738, p = 4.60 × 10−9 , OR =
1.32) (43). Both PLG and P4HA2 play a role in the regulation of
angiogenesis and vascular remodeling. The plasminogen system
is known to regulate several pathways possibly related to the GCA
pathogenesis, such as lymphocyte recruitment and production
of TNF-α and IL-6 cytokines (96, 97). The P4HA2 gene is a
hypoxia-responsive gene with a role in collagen biosynthesis
and composition of ECM. Hypoxia-inducible factor-1 (HIF-1)
regulates the expression of P4HA2 and other genes, such as VEGF,
IL6, and MMP9 (98).

and serum level of IL-6 can be used to stratify patients for antiIL6 treatment (81). Another risk allele, rs6871626, in IL12B is
shown to influence the expression of IL-12p70 and IL-12p40
genes, resulting in enhanced IL-12 signaling that might further
contribute to the pathophysiology of TAK (82). Terao et al.
showed that interaction of HLA-B∗ 52 and LILRB1 may be
responsible for activation of natural killer (NK) cells by a way of
suppression of inhibitory pathways (41).
FCGR2A/FCGR3A is a common susceptibility gene locus for
TAK and KD. The Fc-gamma receptors (FcγRs) are responsible
for interactive relationship between adaptive and innate immune
systems. All immune cells possess these receptors. FcγRs can be
classified into one high-affinity receptor (FcγRI) and five lowaffinity FcγRs (the different isoforms of FcγRII and FcγRIII) (83).
Genetic variants of these receptors have been associated with
susceptibility to autoimmune, autoinflammatory, and infectious
diseases and response to immunotherapy in cancer patients
(6, 84–91). Nagelkerke et al. (51) showed that activation of IgG
receptors on monocytes and neutrophils plays a role in the
pathophysiology of KD. Inhibition of this activation may be a
targeted treatment for patients who carry the FCGR2A/FCGR3A
risk alleles.

Immunoglobulin A
Vasculitis/Henoch-Schönlein Purpura
(IgAV/HSP)
IgAV/HSP is a small-vessel vasculitis of the skin, kidney,
gastrointestinal tract, and joints. IgAV/HSP has typically a good
prognosis because of the self-limiting disease course; however,
renal and gastrointestinal involvement can cause morbidity.
IgAV/HSP is the most common childhood vasculitis. Diagnosis
of IgAV/HSP is based on clinical features; however, skin and
kidney biopsy are useful for diagnosis in selected cases.
The first GWAS of IgAV/HSP revealed that the HLA class II
region (mainly HLA-DRB1∗ 01 allele) in the European population
is associated with the risk for IgAV/HSP, although this finding
did not reach genome-wide significance (42). A meta-analysis
confirmed that genetic susceptibility to IgAV/HSP is associated
with HLA-DRB1∗ 01 and HLA-DRB1∗ 07 variants and suggested
that IgAV may be an HLA class II disease (92). Immunoglobulin
A vasculitis with nephritis (IgAVN) and IgA nephropathy (IgAN;
also known as Berger’s disease) are considered related diseases.
The chromosome 1q32 locus that contains the complement
factor H (CFH) was identified as an IgAN-susceptible locus. Jia
et al. showed the contribution of rs6677604 allele in CFH to
the regulation of the complement activation in both IgAN and
IgAVN (93).

EPIGENETICS AND EPIGENOME-WIDE
ASSOCIATION STUDIES (EWAS) IN
PRIMARY SYSTEMIC VASCULITIDES
Epigenetic mechanisms including DNA methylation, histone
modifications, and non-coding RNAs regulate gene expression,
cellular development, differentiation, and activity (99).
Epigenomic alterations are not the result of genetic mutations,
and they are reversible; however, they can act as integrators of
genetic and environmental disease risk factors. Recent work has
suggested that epigenome modifications, for example, histone
modifications and micro RNA (miRNA) expression, may be used
as a biomarker for disease activity and for monitoring disease
progression (100). EWAS aim to identify epigenetic variations
associated with disease, for example, differentially methylated
CpG sites, by performing a hypothesis-free testing across the
whole genome (101). Thus far, EWAS have mainly investigated
DNA methylation and its association with human diseases. In
general, hypermethylation of promoters typically acts to repress
gene transcription.

Giant Cell Arteritis (GCA)
GCA is a systemic vasculitis characterized by granulomatous
inflammation of medium- and large-sized vessels and with
particular predilection for the aorta and its extracranial branches.
GCA is the most common vasculitis in the elderly (mostly
women) population from western countries (94). GCA can
cause headaches, visual loss, jaw claudication, painful scalp,
impairment of limb arteries, systemic inflammation, and
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immunoglobulin gamma Fc region receptor II-a protein
that is expressed on the surface of macrophages, neutrophils,
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monocytes, and dendritic cells. This protein leads to increased
phagocytosis and production of inflammatory mediators.
Genetic variants in FCGR2A gene have been linked to a genetic
risk for KD (100, 102). The first study to examine the DNA
methylation array in KD showed that CpG sites within the
promoter region of FCGR2A were hypomethylated in whole
blood cells from KD patients compared with controls, and
especially in patients resistant to IVIG treatment (103). Li
et al. demonstrated that DNA methylation patterns changed
after IVIG treatment in KD, including reversal of the diseaseassociated hypomethylation in FCGR2A (104). Furthermore,
interaction of FCGR2A and Toll-like receptors (TLR) can induce
a proinflammatory response (105, 106). DNA hypomethylation
on Toll-like receptors (TLRs) was detected in KD patients, and
the methylation level of the TLRs genes was rescued 3 weeks
post-IVIG therapy (107).
FoxP3 acts as both transcriptional activator and repressor in
regulatory T cells (Tregs), and FoxP3-dependent transcriptional
program is epigenetically controlled by histone modifications
at its binding site (108). FoxP3 binds to ∼700 genes and a
number of miRNAs, including miRNA-155, which upregulation
likely contributes to proliferative potential of TR cells. FoxP3
expression in Tregs of patients with KD is affected by miR-155
and miR-31. In patients with acute KD, decrease in FoxP3+ Treg
might be associated with reduced expression of miR-155 and
overexpression of miR-31. These effects were partially reversed
following the IVIG treatment (109).
Huang et al. (110) showed that the expression of a neutrophil
surface molecule, CD177, is higher during acute stage of KD and
correlates with epigenetic hypomethylation. They observed that
the CD177 mRNA level diminished sharply after IVIG treatment
and were higher in patients with atypical presentation or KD or
IVIG-resistant patients.
Chang et al. (111) recently published that gene expression
of PHLPP1 and MAPK14 is significantly high in KD and is
influenced by methylation. They proposed that hypomethylation
status and upregulated expressions of MAPK14 and PHLPP1
could be candidate biomarkers for the diagnosis of KD.
Hepcidin, encoded by the HAMP gene, has a main role in the
pathogenesis of inflammation-associated anemia. Hepcidin levels
are high in KD patients, and they decrease after IVIG treatment.
Huang et al. demonstrated that KD patients had a considerably
higher epigenetic hypomethylation of HAMP promoter than
controls, which was reversed following therapy with IVIG. They
proposed that HAMP promoter hypomethylation and increased
hepcidin levels may serve as a biomarker of KD (112). Huang
et al. (113) performed the first genome-wide DNA methylation
and gene expression assays in blood samples of KD patients.
They found that specific CpG markers were hypomethylated
in samples from patients with active disease compared to
controls and hypermethylated in samples from patients in
convalescent phase compared with samples from patients in
acute phase. In particular, methylation changes of CpG markers
correlated with the expression S100A genes. S100A8 and
S100A9 are inflammatory biomarkers that are usually highly
expressed in acute and chronic inflammation. Using in vitro
model, they showed that S100A proteins enhanced leukocyte
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transendothelial migration of neutrophils. In summary, this
study implicates the role of S100A proteins in the pathogenesis of
KD (113).

Behçet’s Disease
The first EWAS in BD showed that CD4+ T cells and
monocytes extracted from the peripheral blood of BD patients
were hypomethylated in genes associated with cytoskeletal
remodeling, cell migration, and tissue invasion, such as RAC1,
RGS14, and FSCN2. Some methylation deficiencies return to
normal level during disease remission. These findings suggest
that epigenetic modifications of cytoskeleton-related genes are
important in the pathogenesis of BD (114). Hypermethylation
of the IL-4, TGF-β, and GATA binding protein 3 (GATA3)
in CD4+ cells was noted in patients with active BD, but this
may not be disease-specific (115, 116). Conversely, treatment
with corticosteroids and cyclosporine (CsA) has beneficial effects
by decreasing the methylation level of TGF-β and GATA3
(115). A systematic analysis of miRNA expression profiles and
pathway analyses in BD identified a specific miRNA signatures
in active disease that regulated the IFNγ , TNF, and VEGFVEGFR signaling cascades (117). Woo et al. (118) observed
differential expressions of miRNAs miR-638 and miR-4488 to
be associated with elevated production of IL-6. Activation of
the Notch pathway in active BD disease and its association with
decreased expression of mir-23 and higher Th17 response have
been observed (119). Two functional variants, rs2910164 (miR146a) and rs11614913 (miR-196a2; Ets-1), confer the risk for BD
in Han-Chinese by regulating production of proinflammatory
cytokines (120, 121).
The differentially expressed genes identified by EWAS might
be good candidate biomarkers for monitoring the disease activity
and might represent promising candidates for design of novel
therapeutic strategies in BD.

ANCA-Associated Vasculitis
Normally, the expression of MPO and PRTN3 genes (encoding
MPO and PR3 autoantigenes) in neutrophils occurs only in the
early stages of cell maturation; however, MPO and PRTN3 are
found continuously expressed in neutrophils and monocytes of
patients with AAV (122). This deregulation in gene expression
is postulated to be related to epigenetic mechanisms (123–
125). Jones et al. (124) showed that the gene-specific DNA
methylation changes may regulate autoantigen expression, and
they correlate with disease activity in AAV. In remission,
DNA methylation is generally increased. Patients with active
disease had hypomethylation and increased expression of MPO
and PRTN3. The findings suggest that the reactivation of
once-silenced genes can lead to increased antigen availability.
Patients with decreased DNA methylation at the PRTN3
promoter have a significantly greater risk of relapse. Therefore,
fluctuations in the DNA methylation of the PRTN3 promoter
may be associated with stable remission. Methylation status
may prove to be a potential biomarker for prognosis in AVV
patients (124).
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are released by almost all eukaryotic cells during cell activation
and programmed cell death (131–134). Heterogeneity of EVs is
essential. They are classified into three groups with regard to
biological features and their size: exosomes, microvesicles (MVs),
and apoptotic bodies (132, 133, 135, 136). EVs are responsible
for immune regulation, cell-to-cell interaction, and signal
transmission by transporting bioactive molecules including
proteins and lipids, DNA, and various RNAs, such as mRNAs,
small-interfering RNAs (siRNAs), microRNAs (miRNAs), and
long non-coding RNAs (lncRNAs) and other molecules produced
by cells (132, 137–139). EVs can be detected in many organs,
tissues, and all body fluids, such as urine, blood, and synovial fluid
at low levels in physiological conditions (140, 141). The increased
levels of EVs are noted in cardiovascular disease, cancer,
and pathological conditions that are associated with vasculitis:
inflammation, autoimmunity, endothelial damage, angiogenesis,
procoagulation, and intimal hyperplasia (131–133, 136, 140–
142). EVs are known to be released from injured endothelial
cells and are found increased in many diseases associated with
endothelial dysfunction. It is thought that EVs from platelets,
lymphocytes, and monocyte/macrophages contribute to the
pathogenesis of systemic vasculitis (143–170) (Table 3).
In 2004, Brogan et al. (143) reported that the endothelial
microparticles expressing E-selectin-positive or CD105 and the
platelet MVs expressing CD42a were significantly increased
in patients with active vasculitis compared to controls or
children with inactive vasculitis or other febrile illnesses. They
found that endothelial microparticle levels correlate with the
Birmingham Vasculitis Activity Score (BVAS) and acute-phase
reactant levels (143).
Activation of the contact system has proinflammatory and
vasoactive properties. The contact system triggers the kallikreinkinin cascade releasing bradykinin from high-molecular-weight
kininogen. Bradykinin concentrations were higher in the
patients’ plasma than in plasma from controls, and kinins were
present in lesional biopsy tissues of kidney and skin of children
with PSVs (173, 174). The kinin B1 receptor is induced by
inflammatory stimuli, particularly in response to the cytokine
IL-1β, and plays a major role in neutrophil recruitment. Kahn
et al. (151) found that leukocyte-derived MVs transfer functional
kinin B1-receptors and in this way may further promote kininmediated inflammation in vasculitis. Mossberg et al. (156)
showed that patients with acute vasculitis had significantly
higher levels of circulating endothelial MVs and more MVs
carrying B1-receptors. These MVs can induce the inflammation
by increasing neutrophil chemotaxis, whereas addition of a C1inhibitor decreased the release of B1R+MVs. Kinin-B1 receptor
activation of CXCL5 can further amplify neutrophil chemotaxis
and chronic inflammation (175). Exploring inhibition of the
kallikrein-kinin pathway is potentially a novel target for reducing
neutrophil-mediated inflammation in PSVs.

Luo et al. (126) observed that global histone H3 acetylation
and H3K4 methylation are increased in peripheral blood
mononuclear cells (PBMCs) isolated from IgAV patients. These
epigenetic modifications had positive correlations with disease
activity and were more common in IgAV patients with
renal involvement compared with IgAV patients without renal
involvement and healthy controls. They observed increased
mRNA expression of GATA3, IL-4, IL-6, and IL-13 genes in
IgAV patients. Serum protein levels of IL-4, IL-6, and IL-13
were significantly increased in HSP with kidney damage patients
compared to healthy controls. Abnormal histone modifications
of transcription factors such as GATA3 may lead to the Th1/Th2
cytokine imbalance in HSP and other immune diseases (126).

Giant Cell Arteritis
Only two epigenetic studies evaluated DNA methylation status
and miRNA expression in temporal artery biopsies (TABs) of
patients with GCA (127, 128). Coit et al. (127) identified 1,555
hypomethylated CpG sites in 853 genes by comparing 12 patients
and 12 healthy age-, gender-, and ancrestry-matched controls.
DNA was extracted from the affected temporal artery tissues in
patients with GCA and from histologically confirmed normal
arteries in controls.
Most of these genes have roles in T-cell activation and
differentiation pathways, especially Th1 and Th17 cells. TNF,
LTA, LTB, CCR7, RUNX3, CD6, CD40LG, IL2, IL6, NLRP1,
IL1B, IL18, IL21, IL23R, and IFNG were proinflammatory
hypomethylated genes that were found in this study.
Interestingly, the significant hypomethylation of genes in
the calcineurin (CaN)/NFAT pathway was shown within the
temporal artery of GCA patients.
Increased activity in NFAT is one of the key factors in
production of proinflammatory cytokines. This study provided
evidence for use of NFAT inhibitors (e.g., dipyridamole) in the
treatment of GCA (127, 129).
Croci et al. showed that miR-146b-5p,−146a,−21,−150,−155,
and−299-5p are expressed at higher levels in affected vessels
of TAB-positive GCA patients compared to non-inflamed
TABs from GCA patients and to non-inflamed TABs from
non-GCA patients. Interestingly, these miRNAs were mainly
deregulated at the tissue level, whereas no difference in their
expression was observed in peripheral blood mononuclear
and polymorphonuclear cells from these three groups of
patients and controls. Especially, miR-146b-5p expression was
the most promising diagnostic biomarker for the presence of
inflammation in TABs of GCA patients and the follow up of the
disease activity. Further research is necessary to optimize their
use in medical practice (128).

EXTRACELLULAR VESICLES IN PRIMARY
SYSTEMIC VASCULITIDES

Kawasaki Disease
Endothelial cell-derived MVs were detected in higher levels in
children with KD (147–149, 163, 166) and HSP (144). These MVs
may serve as biomarkers to predict coronary artery aneurysms in
KD and to detect subclinical inflammation in HSP (144, 148).

EVs were defined in 1967 as “dust” from platelets (130). More
recently, it has been shown that EVs are membrane vesicles that
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TABLE 3 | The role of extracellular vesicles in vasculitis. This table is adapted from Wu et al. (133).
Author and references

Origin of EVs

Content of EVs

Related diseases and
vessels

Possible pathogenic mechanism

Nakaoka et al. (147)

Endothelial cells, CD144

miR-145-5p,
miR-320a

KD, medium vessels

Upregulation of proinflammatory
cytokine

Microvesicles

Raposo et al. (136)

Leukocytes CD45

B1-receptors

AAV, IgAV, small vessels

Kinin system

Raposo et al. (136)

Endothelial cells

B1-receptors

AAV, IgAV

Kinin system

Macey et al. (153)

Platelets CD42a/CD62P

–

BS

Inflammation

Dursun et al. (144)

Endothelial cells

–

IgAV/small vessels

Inflammation

Daniel et al. (167)

Neutrophils CD66b

–

AAV

Inflammation and procoagulation

Mendoza-Pinto et al. (171)

Neutrophils annexin

Tissue factor

AAV

Inflammation and thrombosis

Hong et al. (172)

Annexin V neutrophils

CD18/C, D11b, PR3, MPO

AAV

Inflammation and procoagulation

Huang et al. (161)

Annexin V

Tissue factor

AAV

Procoagulation

Mejia et al. (155)

Annexin V

–

BD

Procoagulation

Khan et al. (152)

Annexin V

Tissue factor

BD

Procoagulation

Eleftheriou et al. (145)

Annexin V, platelets CD41
endothelial cells CD62E

Tissue factor

MPA, GPA, PAN, KD, BS

Procoagulation

Martinez et al. (154)

Platelets CD6

–

BS

Procoagulation

Yahata et al. (170)

Platelets CD42b/CD42a

–

KD

Evaluation of platelets

Kim et al. (169)

Annexin V

–

KD

Evaluation of platelets

Hajj-Ali et al. (146)

Annexin endothelial cells
CD105/CD144, platelets
CD41, leukocytes CD18,
neutrophils

–

GPA/small vessels

Platelets activation and endothelial
damage

Tian et al. (166)

Annexin V V/CD62E/CD31

–

KD/medium vessels

Endothelial damage

Erdbruegger et al. (168)

Annexin V, endothelial cell
CD105/CD6 2E

–

AAV/small vessels

Endothelial damage

–

KD/medium vessels

Endothelial dysfunction

Kumpers et al. (165)

Annexin V

–

CSS/small vessels

Endothelial damage

Clarke et al. (162)

Annexin V, endothelial cell

–

MPA, GPA, PAN, KD, BS

Endothelial damage

Guiducci et al. (160)

Platelets CD42,
erythrocytes, T cells,
endothelial cells

–

KD/medium vessels

Endothelial damage

Brogan et al. (143)

Annexin V, platelets
CD42a/CD62

–

MPA, GPA, PAN, KD, BS

Endothelial activation

Tan et al. (149)

Endothelial cells
CD31/CD146

–

KD/medium vessels

Endothelial damage

Shah et al. (148)

Endothelial cells
CD105/CD62E

–

KD/medium vessels

Endothelial damage

Ding et al. (163)

Exosomes
Jia et al. (150)

CD9/CD81/TS

miR-1246, miR44

KD/medium vessels

Diagnostic biomarker

Zhang et al. (159)

–

miR-328, miR-575, miR134, miR-671- 5p

KD/medium vessels

Inflammation

Zhang et al. (158)

CD9/CD81/flotilin

38 different contents

KD/ medium vessels

Inflammation and procoagulation

Zhang et al. (157)

CD9/flotillin

69 different proteins

KD/medium vessels

Inflammation and procoagulation

and the levels were reduced by IVIG treatment (160). Platelet
activation is important in the pathogenesis of KD, thus PDMVs
may serve as a biomarker to evaluate the antiplatelet therapy
response in KD (169, 170).
Measuring microRNAs (miR-4436b-5p, miR-1246, miR-6715p, and miR-197-3p) in serum exosomes has been proposed
as a diagnostic biomarker for the prediction of IVIG response
in KD (149, 159). Serum exosomal microRNAs may have a

The role of platelet activation dynamics in acute-phase
KD patients was explored by assaying platelet-derived MVs
(PDMVs). Prior to aspirin treatment, PDMV level was
significantly higher in the acute-phase KD patients in comparison
to patients with common febrile diseases. Guiducci et al. observed
that MVs derived from platelets, endothelial cells, erythrocytes,
and T cells are significantly elevated in plasma samples of patients
with KD. Endothelial and T cells were the major source of MVs,
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INSIGHTS FROM STUDIES OF
MONOGENIC SYSTEMIC
AUTOINFLAMMATORY DISEASES

role in the pathogenesis of KD by regulating the expression
of inflammatory genes (CX chemokine receptor types 1 and
2, IL-8, and its receptor) in mononuclear cells (159). Serum
exosomes from patients with KD contain many proteins,
such as apolipoprotein A-IV, insulin-like growth factor-binding
protein complex, acid-labile subunit and complement C3, and
their proteomic profile correlates with IVIG therapy (157).
Zhang et al. performed proteomic analyses of serum exosomes
from KD patients with coronary artery dilatation. They found
38 differentially expressed proteins, and the majority are
involved in inflammatory and coagulation pathways (158).
More recent proteomic analysis validated TN, APOA4, LRG1,
and RBP4 proteins as differentially expressed in patients with
coronary artery aneurysms (CAA) (176). These finding provide
additional insights in the pathogenesis of CAA in patients
with KD.

Rare Mendelian diseases of systemic inflammation often present
with severe-like phenotypes of polygenic diseases and can share
underlying biochemical pathways with more common rheumatic
diseases. Identification of patients with monogenic disease can
point to genes and pathways that could be investigated in patients
with polygenic disorders. For instance, polyarteritis nodosa
(PAN) can present either as early-onset monogenic or lateonset polygenic disease. PAN is a systemic necrotizing vasculitis
that predominantly affects medium-sized arteries, causing tissue
ischemia and organ damage. The disease commonly affects the
skin, gastrointestinal tract, and kidneys, and patients are at an
increased risk of stroke. Most cases of PAN occur in the fourth
or fifth decade, and men are more likely to be affected. A
subset of patients with childhood-onset PAN are found to carry
biallelic loss of function mutations in adenosine deaminase 2
gene. This disease is named deficiency of ADA2 (DADA2)(179,
180). Among many features of DADA2, subcortical ischemic
strokes, hypertension, aneurysms, renal infarcts, and peripheral
amputations have been reported in up to 50% of patients. DADA2
patients are highly responsive to treatment with TNF inhibitors
(181). Although pathogenic variants in the ADA2 gene may not
account for a large number of sporadic adult-onset PAN patients,
TNF inhibitors should be explored in the treatment of those
patients as well (181).

ANCA-Associated Vasculitis
Endothelium-derived MVs have been reported in active AAV
patients (168). Plasma levels of MVs derived from platelet
and neutrophil are high in acute-phase vasculitis (167).
The neutrophil-derived MVs cause increased production of
proinflammatory cytokines IL-6 and IL-8, increased expression
of intercellular adhesion molecule-1, and production of reactive
oxygen radicals by binding to endothelial cells in a CD18dependent manner (172). Furthermore, endothelial MVs carry
PR3 and MPO and may contribute to the extensive endothelial
damage and inflammation seen in AAV (177, 178).
Thromboembolic disease complicating primary systemic
vasculitis is associated with significant morbidity and mortality.
The mechanisms of hypercoagulability in PSV remain poorly
defined. Several studies attempted to identify risk factors
of thrombosis to stratify patients who could benefit from
prophylaxis with antiplatelet or anticoagulant agents. One
study showed that stimulation with ANCAs causes C5a-primed
neutrophils to release neutrophil tissue factor (TF)-expressing
MVs and neutrophil extracellular traps (NETs) that might
promote hypercoagulability in AAV (161). Eleftheriou at al.
have demonstrated that thromboembolic disease in children with
systemic vasculitis is linked to increased level of MVs-mediated
thrombin (145).

Inflammasomopathies
Inflammasomopathies are rare monogenic autoinflammatory
diseases caused by gain-of -function mutations in the
multiprotein complexes termed the inflammasome. The
inflammasome functions as cytosolic pathogen and dangerassociated molecular patterns (PAMPs/DAMPs) recognition
receptors (PRRs). The core of inflammasome is one of the
nucleotide-binding domain leucine-rich repeat (NLR) proteins
(NLRP1, NLRP3, AIM2, NLRC4) or pyrin. Upon stimulation,
the inflammasome interacts with an inflammasome adaptor
protein, apoptosis-associated speck-like protein with a caspase
recruitment domain (ASC), or with pro-caspase 1 to form
platform for caspase-1-mediated production of IL-1β and
IL-18 cytokines. The best known inflammasomopathies are
familial Mediterranean fever (FMF) and cryopyrinopathities
(CAPS). FMF is caused by recessively inherited hypomorphic
mutations in pyrin, whereas CAPS is linked to dominantly
inherited gain-of-function mutations in NLRP3. The net effect
of these pathogenic variants is increased production of IL1β cytokine and systemic inflammation. FMF is a common
disease in many Eastern Mediterranean countries where the
frequency of pathogenic mutations is very high (182–205).
Although vasculitis is not a primary feature of FMF, IgAV and
PAN have been reported in about 3 and 1% of FMF patients,
respectively (206). FMF-associated mutations predispose to
the development of BD in the Turkish population (207–210).
Small and medium vessel skin vasculitis and CNS vasculitis were

Behçet’s Disease
Thrombosis is common in BD patients, and there is a need
for better assessment of risk factors. BD patients with a history
of thrombosis have high serum levels of MVs expressing tissue
factor (TF). The ratio of TF pathway inhibitor (TFPI)-positive
MVs to TF-positive MVs was significantly lower in patients
with thrombosis (152). In contrast, platelet-derived MVs and
procoagulant MVs did not differentiate between BD patients with
or without thrombosis (155). Macey et al. (153) showed that highlevel platelet-derived CD62P+ MVs correlate with active disease
in patients in a younger age group, whereas lower levels of MVs
correlate with decreased disease activity in patients older than
50 years.
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mutations in the TMEM173 gene lead to a constitutively
active STING protein, and a high expression of type I IFNinduced genes (235, 236). Clinically, the SAVI phenotype
mimics the AAV with cutaneous rashes, interstitial lung disease,
peripheral ulcerations/gangrene, and ANCA positivity in some
patients (237). Patients with CANDLE have dysfunction in the
protesome-mediated degradation pathway. Skin biopsies from
CANDLE patients showed evidence for perivascular infiltration
prominent for myeloid cells and leukocytoclasis but not for the
typical vasculitis with fibrinoid necrosis of the vessel walls (238).
JAK1/2 inhibition with baricitinib has been successful in treating
clinical disease manifestations and in suppression of the IFN
signature (239). The role of the IFN pathway in the pathogenesis
of polygenic/complex vasculitides has been recently postulated
by analysis of data from multiple GWAS (78).
Reports of vasculitis in other rare autoinflammatory diseases
are scarce. One patient with the deficiency of IL-1 receptor
antagonist (DIRA) had histopathological evidence of vasculitis
in the connective tissue and cerebral vasculitis or vasculopathy
was detected on magnetic resonance imaging (240). IL-1Radeficient mice frequently develop aortitis at the root of the aorta,
which can be suppressed by a cross with TNF-α-deficient mice.
Bone marrow transplantation of T cells from IL-1Ra−/− mice
induced aortitis in recipient nu/nu mice or in irradiated wildtype recipient mice (241). This study demonstrates that IL-1Ra
deficiency in T cells is responsible for the development of aortitis.

reported in other inflammasomopathies, including CAPS and
other pyrin-mediated autoinflammatory diseases mevalonate
kinase deficiency/hyperimmunoglobulin D (MKD/HIDS);
pyogenic arthritis, pyoderma gangrenosum, and acne (PAPA);
and pyoderma gangrenosum, acne, hidradenitis suppurativa
(PASH) syndromes (211–221). NLRP3 inflammasome activation
was demonstrated in two Kawasaki mouse models (222, 223).
Underlying mechanisms of vasculitis in inflammasomopathies
are unclear, although it is assumed that high systemic IL-1β
production may cause endothelial cell inflammation and
damage. Patients with BD may respond to colchicine and
anti-IL1 therapies like patients with inflammasomopathies (224).

Relopathies
Relopathies are NF kappa-B (NF-κB)-mediated monogenic
systemic autoinflammatory diseases driven by multiple
cytokines including TNF and IL-6 (225). They result from
pathogenic variants in proteins that regulate posttranslational
ubiquitin modifications in the NF-κB pathway. Up to now,
haploinsufficency of A20 (HA20) and OTULIN deficiency have
been defined as relopathies (226). HA20 is a dominantly inherited
disease caused by heterozygous loss-of-function mutations in
TNFAIP3, which encodes the K-63 deubiquitinase protein A20
(227). Common variants in TNFAIP3 have been linked to BD in
the Chinese-Han population (228). Clinically, HA20 resembles
early-onset BD. Two patients with HA20 were diagnosed
with CNS vasculitis based on brain imaging and a frontal
lobe punctate (229). OTULIN deficiency is caused by recessively
inherited loss-of-function mutations in the enzyme that regulates
linear deubiquitination. There are only few patients reported,
and they present with early-onset severe systemic inflammation.
One patient was described with vasculitis of small and medium
vessels on skin biopsy (230). In most patients with HA20 and
OTULIN deficiency, anti-cytokine therapies targeting TNF and
IL-1 are efficient in suppressing the disease activity. Ubiquitin
pathway has been implicated in the pathogenesis of BD by
multiple association studies. The rs9517723 variant in the 3’
region of ubiquitin-associated domain containing ubiquitinassociated domain containing 2 (UBAC2) gene is significantly
associated with ocular and central nervous system (CNS) lesions
under the recessive model (32, 231). UBAC2 encodes a protein
that plays a role in ubiquitination and proteasomal degradation.
Homozygous risk allele (TT) of the rs9517723 correlates with
increased UBAC2 expression. BD has been also associated with
other ubiquitination pathway-related genes, including ubiquitin
associated and SH3 domain containing B (UBASH3B) and small
ubiquitin-like modifier 4 (SUMO4) (232, 233).

EXPERT COMMENTARY
i) The main limitations of current genetic datasets in PSVs
are the lack of multiple meta-analyses of GWAS and
inability to confirm functional significance of identified risk
alleles. Validation of disease-associated variants in cohorts of
patients of different ancestry would give more creditability
to the reported findings; however, some genetic variants may
not be present in all populations.
ii) As epigenetic modifications evolve and change over the
life span, the data from EWAS will require validation in
longitudinal cohort studies that are costly to maintain.
Epigenomic investigations maybe accomplished in a shorter
time period if they focus on studies in monozygotic twin
pairs (MZ pairs) or if they would investigate differences in
young vs. old MZ pairs. In addition, it would be interesting
to explore cell-specific epigenomic modifications.
iii) Use of extracellular vesicles (MVs, PDMVs, EMVs) as
potential biomarkers of disease activity in patients with
primary systemic vasculitis is important for diagnostic
and treatment monitoring. At present time, there are
no standardized methods for the sampling process and
detection of EVs.

Interferonopathies
Type I interferonopathies consist of Aicardi–Goutières
syndrome (AGS), STING-associated vasculopathy with onset
in infancy (SAVI), chronic atypical neutrophilic dermatosis
with lipodystrophy and elevated temperature (CANDLE)
syndrome, and COPA syndrome (226). Intracerebral vasculitis
is common in patients with AGS (234). High levels of IFN
activities were demonstrated in the cerebrospinal fluid and
serum of AGS patients (234). In SAVI, gain-of-function
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Multicenter collaborations and studies in large cohorts of patients
would increase the power of detection and confirmation of PSV
disease-associated variants. These meta studies would also help
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proteomic, and metabolic variants and epigenomic biomarkers
to generate “omic” profiles. The translation into clinical practice
can be achieved by integrating the “omic” information into
a unique algorithm that will be able to make accurate
diagnosis and to optimize therapeutic decisions to maximize
benefit and minimize harm. Proper implementation of PM will
require multidisciplinary teams of clinicians, bioinformaticians,
geneticists, genetic counselors, and research scientists that can
address multiple challenges in interpretation and integration of
the multi-omics results. Along these lines, successful transition
toward personalized care will also necessitate updating medical
curriculums to facilitate training of a new generation of “omic”literate physicians.

estimate a size effect of identified risk alleles, which is important
for calculation of genetic risk score (GRS) and genetic counseling.
Considering a significant decrease in the cost of whole exome and
whole genome sequencing (WES/WGS), these new sequencing
technologies should capture rare germ-line variants, structural
variants, and mosaic mutations that may explain the missing
heritability in these diseases. At this time, it is still unclear
whether SNPs captured by GWAS are true disease-associated
variants or in linkage disequilibrium with a risk allele. Performing
WGS of patient cohorts would avoid a need for imputation
studies. Effects of most common disease-associated variants
on protein function are unclear, in particular for non-coding
variants. Disease-associated common variants may have very
small effect sizes but could lead to important and targetable
pathways. Studies in cell culture systems and model organisms
and experiments in primary patient cells are needed to answer
this question.
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